Mangoceuticals (NASDAQ:MGRX) Announces Earnings Results

Mangoceuticals (NASDAQ:MGRX) announced its quarterly earnings data on Wednesday. The company reported $0.13 EPS for the quarter, Zacks reports. Mangoceuticals had a negative return on equity of 114.63% and a negative net margin of 4,253.43%.The company had revenue of $0.09 million for the quarter.

Mangoceuticals Price Performance

NASDAQ MGRX traded down $0.02 during trading on Thursday, reaching $0.34. 376,918 shares of the company’s stock traded hands, compared to its average volume of 12,301,212. Mangoceuticals has a 12-month low of $0.16 and a 12-month high of $2.88. The firm has a market cap of $5.60 million, a price-to-earnings ratio of -0.10 and a beta of 2.54. The company’s 50 day simple moving average is $0.40 and its two-hundred day simple moving average is $1.15.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Mangoceuticals has a consensus rating of “Sell”.

Hedge Funds Weigh In On Mangoceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of MGRX. Armistice Capital LLC bought a new position in Mangoceuticals in the fourth quarter worth approximately $1,137,000. Ikarian Capital LLC purchased a new position in shares of Mangoceuticals in the 4th quarter valued at $102,000. Jane Street Group LLC purchased a new position in shares of Mangoceuticals in the 4th quarter valued at $35,000. Boothbay Fund Management LLC bought a new position in shares of Mangoceuticals in the 4th quarter worth $28,000. Finally, Virtu Financial LLC purchased a new stake in shares of Mangoceuticals during the 4th quarter worth $25,000. 56.72% of the stock is currently owned by institutional investors.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.